Views 442
Citations 0
Global Health
March 17, 2015

HIV Prevention Trial in African Women Fails, Adherence a Problem

Author Affiliations

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(11):1093. doi:10.1001/jama.2015.2059

Three antiretroviral products evaluated among African women in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) HIV prevention trial were found to be safe but, because of poor adherence, were not effective in preventing sexually acquired HIV (Marrazzo JM et al. N Engl J Med. 2015;372[6]:509-518).

The VOICE trial, a study of tenofovir-based preexposure prophylaxis with or without the oral antiretroviral therapy emtricitabine was conducted from September 2009 to August 2012. More than 5000 women aged 18 to 45 years who were from 15 clinical research sites in Uganda, Zimbabwe, and South Africa were randomized (1:1:1:1:1) to receive 1 of 5 treatments: oral tenofovir disoproxil fumarate, oral tenofovir with emtricitabine, oral placebo, 1% tenofovir vaginal gel, or placebo vaginal gel.

First Page Preview View Large
First page PDF preview
First page PDF preview